In vivo and in vitro pharmacologic profile of two new irreversible MAO-B inhibitors: MDL 72,974A and fluorodeprenyl.
Terleckyj
I A
IA
Department of Neurology, University of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway 08854.
Heikkila
R E
RE
D000498:Allyl Compounds; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000201:enzymology*; D002082:Butylamines / Q000494:pharmacology*; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D051381:Rats; D012642:Selegiline / Q000031:analogs & derivatives* / Q000494:pharmacology
D000498:Allyl Compounds; D002082:Butylamines; D007527:Isoenzymes; D008996:Monoamine Oxidase Inhibitors; C064772:4-fluorodeprenyl; C058000:mofegiline; D012642:Selegiline